Metastatic castration-resistant prostate cancer (CRPC) is a form of prostate cancer that becomes resistant to treatment with hormone therapy. In this case, the hormonal drug no longer provides benefits and other therapeutic options are necessary.
Some prostate cancers are resistant to androgen deprivation therapy. However, there are new therapeutic options available for these patients.